News | February 11, 2026
Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The revenues this quarter are in line with the outlook we envisaged for the year
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The company’s EBITDA margin remained resilient above 20%
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Subscribe To Our Newsletter & Stay Updated
